METHODS: We conducted a cross-sectional study of adults between 18 and 55 years old. Inclusion criteria were: exclusive e-cigarette use or cigarette smoking for ≥ 1 year or no history of tobacco use. Participants with a history of pulmonary illness, atopy, medications (except birth control pills), marijuana, and illegal substance use were excluded. Custom Multiplex ELISA was used to measure YKL-40 and other biomarker levels in the serum and induced sputum of the participants. Multivariable linear regression was used to compare the levels of YLK-40 in healthy participants, e-cigarette, and cigarette users after adjusting for age, sex, and BMI. RESULTS: We recruited 20 healthy controls, 23 cigarette smokers, and 22 exclusive e-cigarette users. Serum YKL-40 (ng/ml) was significantly higher in e-cigarette users (Median 21.2 [IQR 12.1-24.0] ng/ml) when compared to controls (12.2 [IQR 8.7-18.1] ng/ml, p = 0.016) but comparable to cigarette smokers (21.6 [IQR 11.62-51.7] ng/ml, p = 0.31). No significant differences were found in the serum or sputum of the other biomarkers tested. CONCLUSION: The inflammatory biomarker, YKL-40 is elevated in the serum but not the sputum of e-cigarette users with no reported pulmonary disease. Further research is necessary to characterize this association.
METHODS: We conducted a cross-sectional study of adults between 18 and 55 years old. Inclusion criteria were: exclusive e-cigarette use or cigarette smoking for ≥ 1 year or no history of tobacco use. Participants with a history of pulmonary illness, atopy, medications (except birth control pills), marijuana, and illegal substance use were excluded. Custom Multiplex ELISA was used to measure YKL-40 and other biomarker levels in the serum and induced sputum of the participants. Multivariable linear regression was used to compare the levels of YLK-40 in healthy participants, e-cigarette, and cigarette users after adjusting for age, sex, and BMI. RESULTS: We recruited 20 healthy controls, 23 cigarette smokers, and 22 exclusive e-cigarette users. Serum YKL-40 (ng/ml) was significantly higher in e-cigarette users (Median 21.2 [IQR 12.1-24.0] ng/ml) when compared to controls (12.2 [IQR 8.7-18.1] ng/ml, p = 0.016) but comparable to cigarette smokers (21.6 [IQR 11.62-51.7] ng/ml, p = 0.31). No significant differences were found in the serum or sputum of the other biomarkers tested. CONCLUSION: The inflammatory biomarker, YKL-40 is elevated in the serum but not the sputum of e-cigarette users with no reported pulmonary disease. Further research is necessary to characterize this association.
Authors: Chun Geun Lee; Charles S Dela Cruz; Erica Herzog; Stephen M Rosenberg; Farida Ahangari; Jack A Elias Journal: Am J Respir Crit Care Med Date: 2012-04-01 Impact factor: 21.405
Authors: Geoffrey L Chupp; Chun Geun Lee; Nizar Jarjour; Yun Michael Shim; Carole T Holm; Susan He; James D Dziura; Jennifer Reed; Anthony J Coyle; Peter Kiener; Mark Cullen; Martine Grandsaigne; Marie-Christine Dombret; Michel Aubier; Marina Pretolani; Jack A Elias Journal: N Engl J Med Date: 2007-11-15 Impact factor: 91.245
Authors: Denitza P Blagev; Dixie Harris; Angela C Dunn; David W Guidry; Colin K Grissom; Michael J Lanspa Journal: Lancet Date: 2019-11-08 Impact factor: 79.321
Authors: Qixin Wang; Isaac K Sundar; Dongmei Li; Joseph H Lucas; Thivanka Muthumalage; Samantha R McDonough; Irfan Rahman Journal: Respir Res Date: 2020-06-18
Authors: Laura E Crotty Alexander; Christopher A Drummond; Mark Hepokoski; Denzil Mathew; Alex Moshensky; Andrew Willeford; Soumita Das; Prabhleen Singh; Zach Yong; Jasmine H Lee; Kevin Vega; Ashley Du; John Shin; Christian Javier; Jiang Tian; Joan Heller Brown; Ellen C Breen Journal: Am J Physiol Regul Integr Comp Physiol Date: 2018-01-31 Impact factor: 3.210
Authors: Hayden McRobbie; Anna Phillips; Maciej L Goniewicz; Katie Myers Smith; Oliver Knight-West; Dunja Przulj; Peter Hajek Journal: Cancer Prev Res (Phila) Date: 2015-09